Senores Pharmaceuticals Ltd approves Q2FY27 results, reporting ₹192.33 crore revenue, and appoints Talati and Talati LLP as joint auditors for FY27–FY31.
- EBITDA was approximately ₹58 crore, with a 30.2% margin, up 38% year on year and about 290 bps.
- Net profit was ₹36.60 crore, up 21.5% year on year and 20.2% sequentially.
- Limited-review conclusions were unmodified; tax and deferred-tax provisions were based solely on management estimates.